During the 79th World Health Assembly (WHA) in Geneva, MPP will engage both in the formal proceedings of the Assembly and in a number of side events and partner-led discussions.
MPP will contribute statements during WHA deliberations, including under several agenda items, reflecting its role in advancing equitable access to health technologies through public health-driven licensing and technology transfer.
Alongside the Assembly, MPP will take part in discussions focused on innovation, access, global health security and pandemic preparedness, in collaboration with governments, international organisations and industry partners.
Global Health Security: Leveraging Innovation and Partnership for Sustainable Access > Monday 18 May, co‑hosted by MPP and Roche. Invitation only. MPP will co‑host a high-level panel discussion on the role of innovation and public‑private partnerships in strengthening global health security and building resilient health systems, with sustainable access as a core objective.
Aligning the Global Health Architecture for Equitable Access to Health Commodities > Monday 18 May, hosted by France with MPP, supported by the World Health Organization (WHO). Invitation only. MPP will co-convene this fifth high-level dialogue alongside the World Health Assembly, to reflect on how the global health ecosystem can be better aligned to translate innovation into equitable access. The dialogue will examine where greater coordination is needed across research and development, licensing, manufacturing, financing, procurement and delivery, and highlight practical, cost-effective mechanisms that are already delivering results and can be scaled. > Format: Hybrid: in-person (invitation only) and online, with English and French interpretation. Details on online registration will soon be available
Future-Proofing Africa’s Supply Chains: Strengthening Pharmaceutical Systems for Health Emergencies > Tuesday 19 May, co-hosted by MPP, the United States Pharmacopeia (USP) and Unitaid. Invitation only. This roundtable discussion will explore how stronger pharmaceutical systems, regional manufacturing and regulatory preparedness can support faster and more equitable access to essential medicines during health emergencies.
Operationalising the Pandemic Agreement – One Year Later: Progress on Resilient Pipelines for Therapeutics, the Therapeutics Development Coalition, and Market & Access Resilience > Monday 18 May, co‑hosted by Unitaid and the International Pandemic Preparedness Secretariat (IPPS). Invitation only. MPP will participate in this high-level panel discussion marking one year since the adoption of the WHO Pandemic Agreement, focusing on progress in strengthening therapeutic R&D pipelines and advancing access and market resilience to support future pandemic responses.
Not able to join WHA79? Follow us on LinkedIn, X or Bluesky for updates. #WHA79
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.